**Табела. 9.8** Компетентност ментора

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Име и презиме** | | | [Ђорђе Поповић](https://kobson.nb.rs/nauka_u_srbiji.748.html?autor=Popovic%20DS#.YVyEsFVBzIU) | | | | | | | | |
| **Звање** | | | Ванредни професор | | | | | | | | |
| **Ужа научна, уметничка односно стручна област** | | | Интерна медицина, ендокринологија | | | | | | | | |
| **Академска каријера** | | **Година** | **Институција** | | | | **Ужа научна, уметничка односно стручна област** | | | | |
| Избор у звање | | 2018. | Медицински факултет Нови Сад | | | | Интерна медицина- ендокринологија и болести метаболизма | | | | |
| Докторат | | 2016. | Медицински факултет Нови Сад | | | | Клиничка медицина | | | | |
| Специјализација | | 2017. | Медицински факултет Нови Сад | | | | Интерна медицина | | | | |
| Супспецијализација | | 2019. | Медицински факултет Нови Сад | | | | Ендокринологија | | | | |
| Диплома | | 2008. | Медицински факултет Нови Сад | | | | Општа медицина | | | | |
| **Списак дисертација-докторских уметничких пројеката а у којима је наставнк ментор или је био ментор у претходних 10 година** | | | | | | | | | | | |
| Р.Б. | Наслов дисертације- докторског уметничког пројекта | | | Име кандидата | | \*пријављена | | | \*\* одбрањена | | |
| 1. | Утицај терапије инхибитора фактора туморске некрозе на минералну коштану густину и коштане биохемијске маркере-проколаген тип 1Н-терминални пропептид и бета-crosslaps код болесница са реуматоидним артритисом | | | Тања Јанковић | |  | | | 2020. | | |
| 2. | Повезаност степена оштећења јетрене функције и остеосаркопеније у цирози јетре | | | Тања Гламочанин | | 2020. | | |  | | |
| \*Година у којој је дисертација-докторски уметнички пројекат пријављена-пријављен (само за дисертације-докторске уметничке пројекте које су у току), \*\* Година у којој је дисертација-докторски уметнички пројекат одбрањена (само за дисертације-докторско уметничке пројекте из ранијег периода) | | | | | | | | | | | |
| **Категоризација публикације научних радова из области датог студијског програма према класификацији ресорног Министарства просвете, науке и технолошког развоја а у складу са допунским захтевевима стандарда за дато поље** | | | | | | | | | | | |
| **Р.б.** | **Публикација** | | | | | | | | **ISI** | **M** | **IF** |
| 1. | Koufakis T, **Popovic DS**, Papanas N. Should tirzepatide be considered for early management in type 2 diabetes? Pros and cons. Expert Opin Pharmacother. 2023 Jul 18:1-4. doi [10.1080/14656566.2023.2237414](https://doi.org/10.1080/14656566.2023.2237414) | | | | | | | | 147/277 (2022) | 22 (2022) | 3.2 (2022) |
| 2. | Patoulias D, **Popovic DS**, Stoian AP, Janez A, Sahebkar A, Rizzo M. [Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials](https://pdf.sciencedirectassets.com/271280/1-s2.0-S1056872723X00075/1-s2.0-S1056872723001277/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEFsaCXVzLWVhc3QtMSJGMEQCIFmEO21uuXhuEbBhfjrxW%2F8CcKVuvviflZ%2B5dL0Ct7uiAiAPfJyuy7hdzkV%2F7K2wQwhXkxe6OUCdEeEfSTiDbja). J Diabetes Complicat. 2023 Aug;37(8):108529. | | | | | | | | 99/145 (2022) | 23 (2022) | 3.0 (2022) |
| 3. | Bica IC, Stoica RA, Salmen T, Janež A, Volčanšek Š, **Popovic D**, et al. [The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301940/pdf/medicina-59-01136.pdf). Medicina (Kaunas). 2023 Jun 12;59(6):1136. | | | | | | | | 87/168 (2022) | 22 (2022) | 2.6 (2022) |
| 4. | Patoulias D, **Popovic DS**, Fragakis N, Rizzo M. [Has the time come to step up to "triple therapy" for the treatment of diabetic kidney disease?](https://pdf.sciencedirectassets.com/271273/1-s2.0-S0168822723X00072/1-s2.0-S0168822723004898/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEFoaCXVzLWVhc3QtMSJGMEQCIE37BvM7LhOLp2WznfIrJDXlGioxGXKBLm3s9Q7O3o0MAiBLEYyZf86bfRY7Mc2ZogFrc5U8VZWuQx1G5p68MixUqyqyB) Diabetes Res Clin Pract. 2023 Jul;201:110726. doi: 10.1016/j.diabres.2023.110726. | | | | | | | | 37/145 (2022) | 21 (2022) | 5.1 (2022) |
| 5. | Patoulias D, **Popovic DS**. [Are SGLT-2 inhibitors "the elephant in the room" of non-diabetic glomerulonephritis? Considerations about the background immunosuppressive treatment](https://link.springer.com/article/10.1007/s11255-023-03618-w). Int Urol Nephrol. 2023 Apr 29. (Letter) | | | | | | | | 61/88 (2022) | 26 (2022) | 2.0 (2022) |
| 6. | **Popovic DS**, Papanas N. [Contrast-Associated Acute Kidney Injury: More Frequent Among Patients With Diabetic Foot Ulcers](https://journals.sagepub.com/doi/epub/10.1177/00033197231159247). Angiology. 2023 Aug;74(7):609-10. | | | | | | | | 39/67 (2022) | 22 (2022) | 2.8 (2022) |
| 7. | Arvanitakis K, Koufakis T, **Popovic D**, Maltese G, Mustafa O, Doumas M, Giouleme O, Kotsa K, Germanidis G. [GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use](https://link.springer.com/article/10.1007/s13679-023-00506-3). Curr Obes Rep. 2023 Jun;12(2):61-74. | | | | | | | | 12/145 (2022) | 21a (2022) | 8.8 (2022) |
| 8. | **Popovic DS**, Papanas N, Koufakis T, Kotsa K, Mahmeed WA, Al-Rasadi K, et al. Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs - The CAPISCO International Expert Panel. Exp Clin Endocrinol Diabetes. 2023 May;131(5):260-7. doi 10.1055/a-2019-1111 | | | | | | | | 132/145 (2022) | 23 (2022) | 1.8 (2022) |
| 9. | Karras SN, Koufakis T, Dimakopoulos G, **Popovic DS**, Kotsa K[. Changes in dietary intake of aspartic acid during and after intermittent fasting correlate with an improvement in fasting glucose in overweight individuals](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934951/pdf/JDB-15-181.pdf). J Diabetes. 2023 Feb;15(2):181-184. (Letter) | | | | | | | | 43/145 (2022) | 25 (2022) | 4.5 (2022) |
| 10. | **Popovic DS**, Stoian AP, Papanas N. [Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?](https://link.springer.com/article/10.1007/s12020-022-03294-3) Endocrine. 2023 Apr;80(1):232-3. (Letter) | | | | | | | | 75/145 (2022) | 22 (2022) | 3.7 (2022) |
| 11. | Stoian AP, Rizzo M, Salmen T, Kempler P, Stulnig T, Papanas N, **Popovic D**, et al. [Post COVID-19 syndrome related to diabetes - A brief review](https://ceda-diabetes.eu/wp-d8bc7-content/uploads/2022/03/FID_CEDA_Science_Post-COVID-19-Syndrome_DSH2202.pdf). Diabetes Stoffwech H. 2022;31(2):126-30. | | | | | | | | 143/145 | 23 | 0.2 |
| 12. | **Popovic DS**, Stoian AP, Papanas N. [Could cardiorenal benefits of sodium-glucose co-transporter 2 inhibitors be extended to type 1 diabetes mellitus?](https://pdf.sciencedirectassets.com/271280/1-s2.0-S1056872722X00111/1-s2.0-S1056872722002501/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEFsaCXVzLWVhc3QtMSJGMEQCIFmEO21uuXhuEbBhfjrxW%2F8CcKVuvviflZ%2B5dL0Ct7uiAiAPfJyuy7hdzkV%2F7K2wQwhXkxe6OUCdEeEfSTiDbja) J Diabetes Complications. 2022 Nov;36(11):108338. (Letter) | | | | | | | | 99/145 | 26 | 3.0 |
| 13. | **Popovic DS**, Papachristou S, Stokic E, Papanas N. Ezetimibe and Insulin Resistance. Curr Vasc Pharmacol. 2022;20(4):315-7. doi [10.2174/1570161120666220301140528](http://dx.doi.org/10.2174/1570161120666220301140528) | | | | | | | | 77/277 | 21 | 4.5 |
| 14. | **Popovic DS**, Stokic E, Stoian AP, Papanas N. Achieving LDL-cholesterol Targets: How Good are we in the Balkan Region? Curr Vasc Pharmacol. 2022;20(4):311-312. doi [10.2174/1570161119666210921093735](https://doi.org/10.2174/1570161119666210921093735) | | | | | | | | 77/277 | 21 | 4.5 |
| 15. | **Popovic DS**, Koufakis T, Kovacevic B, Rizzo M, Papanas N. [Immune checkpoint inhibitors-induced diabetes mellitus: a growing clinical presentation requiring our attention](https://www.tandfonline.com/doi/epdf/10.1080/14740338.2022.2134343?needAccess=true&role=button). Expert Opin Drug Saf. 2022 Nov;21(11):1337-9. | | | | | | | | 153/277 | 22 | 3.1 |
| 16. | Koufakis T, Maltese G, **Popovic DS**, Kotsa K. [The importance of sleep quality, quantity, and chronotype in the management of diabetes: Is it time to wake up?](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512768/pdf/JDB-14-633.pdf) J Diabetes. 2022 Sep;14(9):633-4. (Letter) | | | | | | | | 43/145 | 25 | 4.5 |
| 17. | **Popovic DS,** Papanas N. Double diabetes: a growing problem requiring solutions. Exp Clin Endocrinol Diabetes. 2022;130(4):268-74. | | | | | | | | 132/145 | 23 | 1.8 |
| 18. | Papachristou S, **Popovic DS**, Papanas N. [Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?](https://link.springer.com/article/10.1007/s12325-022-02125-1) Adv Ther. 2022 Jun;39(6):2283-6. | | | | | | | | 73/136 | 22 | 3.8 |
| 19. | Busnatu SS, Salmen T, Pana MA, Rizzo M, Stallone T, Papanas N, **Popovic D**, et al. [The Role of Fructose as a Cardiovascular Risk Factor: An Update](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779080/pdf/metabolites-12-00067.pdf). Metabolites. 2022 Jan 12;12(1):67. | | | | | | | | 112/285 | 22 | 4.1 |
| 20. | **Popovic DS**, Papanas N, Pantea Stoian A, Rizvi AA, Janez A, Rizzo M. [Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546380/pdf/13300_2021_Article_1170.pdf). Diabetes Ther. 2021 Dec;12(12):3037-54. | | | | | | | | 75/143 (2019) | 22 (2019) | 3.179 (2019) |
| 21. | Papachristou S, **Popovic DS**, Papanas N. [The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?](https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.3503) Diabetes Metab Res Rev. 2021 Nov;37(8):e3503. | | | | | | | | 21/147 | 21 | 8.128 |
| 22. | Papanas N, **Popovic DS**. [Beta-Catenin Signaling Pathway: Perhaps We Should Start Exploring it for Diabetic Foot Ulcer Healing?](https://journals.sagepub.com/doi/epub/10.1177/15347346211029818) Int J Low Extrem Wounds. 2023 Sep;22(3):441-3. | | | | | | | | 51/70 | 23 | 1.922 |
| 23. | Velojic-Golubovic M, Ciric V, Dimitrijevic M, Kovic T, Mitic M, Olujic B, Pevac N, Radenkovic S, Radojkovic D, Vukadinovic S, **Popovic DS**. [Clinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266919/pdf/13300_2021_Article_1074.pdf). Diabetes Ther. 2021 Jul;12(7):2049-58. | | | | | | | | 75/143 (2019) | 22 (2019) | 3.179 (2019) |
| 24. | **Popovic DS,** Rizzo M, Stokic E, Papanas N. [New sub-phenotyping of subjects at high risk of type 2 diabetes: what are the potential clinical implications](https://link.springer.com/content/pdf/10.1007/s13300-021-01065-3.pdf)? Diabetes Ther. 2021;12:1605-11. | | | | | | | | 75/143  (2019) | 22  (2019) | 3.179  (2019) |
| 25. | [**Popovic DS**](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=5778516), [Vukovic B](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=2109223), [Mitrovic M](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=2144114), [Tomic-Naglic D](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=2551746), [Stokic E](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=613902). The predictive value of various visceral adiposity indicators in detecting the presence of impaired fasting glucose. Diabetes Stoffwechsel und Herz. 2020;29(1):17-23. | | | | | | | | 144/145 | 23 | 0.262 |
| 26. | **Popovic DS,** Lelik-Tubic K. Beneficial renal effect of insulin glargine 300 U/ml initiation in type 2 diabetes mellitus patients previously treated with insulin.  Diabetes Stoffwechsel und Herz. 2020;29(6):364-6. | | | | | | | | 144/145 | 23 | 0.262 |
| 27. | [Pejin R](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=6243735), [**Popovic D**](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=31604692), [Tanackov I](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=1306326), [Bjelica A](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=3151668), [Tomic-Naglic D](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=2551746), [Jovanovic A](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=35071948), [Stokic E](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=613902). [The synergistic action of antioxidative enzymes - correlations of catalase and superoxide dismutase in the development and during the treatment of type 2 diabetes](http://www.doiserbia.nb.rs/img/doi/0370-8179/2019/0370-81791900028P.pdf). Srp Arh Celok Lek. 2019;147(5-6):286-94. | | | | | | | | 162/165 | 23 | 0.142 |
| 28. | [Pejin R](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=6243735), [Stokic E](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=613902), [Tanackov I](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=1306326), [**Popovic D**](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=31604692), [Bjelica A](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=3151668), [Jovanovic A](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=35071948)[. Chronic inflammation and lipid profile parameters in obese subjects with normal and disturbed glucose metabolism](http://www.doiserbia.nb.rs/img/doi/0370-8179/2019/0370-81791900017P.pdf). Srp Arh Celok Lek. 2019;147(3-4):173-80. | | | | | | | | 162/165 | 23 | 0.142 |
| 29. | Čabarkapa V,Djerić M, Mitrović M, Kojić-Damjanov S, Isakov I, Vuković B, **Popović Dj**. [Fecal pancreatic elastase-1 and erythrocyte magnesium levels in diabetes type 1 and type 2](https://www.jle.com/download/mrh-312569-39339-fecal_pancreatic_elastase_1_and_erythrocyte_magnesium_levels_in_diabetes_type_1_and_type_2-225054-u.pdf). Magnesium Res. 2018;31(1):1-10. | | | | | | | | 256/299 | 23 | 1.588 |
| 30. | Zivanovic Z, Divjak I, Jovicevic M, Rabi-Zikic T, Radovanovic **B**, Ruzicka-Kaloci S, **Popovic D**, Stokic E, Gebauer-Bukurov K, Zivanovic-Vujcic K, Slankamenac P. Association between Apolipoproteins AI and B and ultrasound indicators carotid atherosclerosis. Curr Vasc Pharmacol. 2018;16(4):376-84. | | | | | | | | 33/65 | 22 | 2.583 |
| 31. | [**Popovic DS**](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=5778516), [Mitrovic M](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=2144114), [Tomic-Naglic D](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=2551746), [Icin T](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=2813972), [Bajkin I](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=2463745), [Vukovic B](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=2109223), [Benc D](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=6937618), [Zivanovic Z](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=1577355), [Kovacev-Zavisic B](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=2308324), [Stokic E](http://ezproxy.nb.rs:2241/OutboundService.do?SID=C3jBPLk3B8ybqy8t1uo&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=613902). The Wnt/beta-catenin signalling pathway inhibitor sclerostin is a biomarker for early atherosclerosis in obesity. Curr Neurovasc Res. 2017;14(3):200-6. | | | | | | | | 105/194  (2016) | 22  (2016) | 2.298  (2016) |
| 32. | **Popovic DS**, Stokic E, Mitrovic M, Tomić-Naglic D, Pejin R, Icin T, Vukovic B, Zivanovic Z, Pejakovic S, Kovacev-Zavisic B. Surrogates of insulin sensitivity and indices of cardiometabolicprofile in obesity. Curr Vasc Pharmacol. 2017;15(4):380-9. | | | | | | | | 131/256  (2016) | 22  (2016) | 2.391  (2016) |
| 33. | **Popovic DS**, Tomic-Naglic D, Mitrovic M, Zivanovic Z, Vukovic B**,** Stokic E. 1h Post-load blood glucose in the identification of proatherogenic cardiometabolic profile in obesity. Endocr Metab Immune Disord Drug Targets. 2017;17(3):226-37. | | | | | | | | 111/142 | 23 | 2013 |
| 34. | [**Popovic DS**,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Popovic%20Djordje%20S) [Stokic E,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Stokic%20Edita%20J) [Tomic-Naglic D,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Tomic-Naglic%20Dragana) [Novakovic-Paro J,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Novakovic-Paro%20Jovanka) [Mitrovic M,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Mitrovic%20Milena%20M) [Vukovic B,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Vukovic%20Bojan) [Kovacev-Zavisic B.](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Kovacev-Zavisic%20Branka) [Circulating sclerostin levels and cardiovascular risk in obesity](http://www.sciencedirect.com/science/article/pii/S0167527316304934). Int J Cardiol. 2016;214:48-50. | | | | | | | | 20/124  (2015) | 21  (2015) | 4.638  (2015) |
| 35. | **Popovic DS**, Stokic E, Popovic SL. GLP-1 receptor agonists and type 1 diabetes - where do we stand? Curr Pharm Des. 2015;21(36):5292-8. | | | | | | | | 74/255 | 21 | 3.052 |
| 36. | **Popovic DS**, Tomic-Naglic D, Stokic E. [Relation of resistin, leptin and adiponectin--trinity of adipose tissue dysfunction assessment](http://ac.els-cdn.com/S0953620514001253/1-s2.0-S0953620514001253-main.pdf?_tid=0acdad04-96bf-11e7-8ef5-00000aab0f01&acdnat=1505113472_80f1b4fded5ae06365aa22a8ea1b8cae). Eur J Intern Med. 2014;25(6):e80-1. | | | | | | | | 26/154 | 21 | 2.891 |
| **Збирни подаци научне активност наставника** | | | | | | | | | | | |
| **Збирни подаци уметничке активност наставника** | | | | | | | | | | | |
| Укупан број цитата, без аутоцитата | | | | | 119 | | | | | | |
| Укупан број радова са SCI (или SSCI) листе | | | | | 48 | | | | | | |
| Тренутно учешће на пројектима | | | | | Домаћи: - | | | Међународни: - | | | |
| Усавршавања | | | | | 2016. | | | Section of Metabolic Diseases and Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Италија | | | |
| 2015. | | | 12th European Association for the Study of Diabetes Robert Turner Clinical Research Course in Oxford, Уједињено Краљевство | | | |
| 2014. | | | Salzburg Weill Cornell Seminar: "Atherosclerosis: Roles of Plasma Lipids, Lipoproteins and Disorders of Metabolism", Аустрија | | | |
| Други подаци које сматрате релевантним | | | | | **-** | | | | | | |

Максимална дужине не сме бити већа од 2 странице А4